- Home
- ZIMV vs FATE Comparison
ZIMV vs FATE Comparison
Compare ZIMV & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZIMV
- FATE
- Stock Information
- Founded
- ZIMV 2021
- FATE 2007
- Country
- ZIMV United States
- FATE United States
- Employees
- ZIMV N/A
- FATE N/A
- Industry
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZIMV Health Care
- FATE Health Care
- Exchange
- ZIMV Nasdaq
- FATE Nasdaq
- Market Cap
- ZIMV 379.2M
- FATE 406.5M
- IPO Year
- ZIMV N/A
- FATE 2013
- Fundamental
- Price
- ZIMV $14.33
- FATE $1.32
- Analyst Decision
- ZIMV Buy
- FATE Hold
- Analyst Count
- ZIMV 2
- FATE 10
- Target Price
- ZIMV $19.50
- FATE $6.75
- AVG Volume (30 Days)
- ZIMV 112.4K
- FATE 3.0M
- Earning Date
- ZIMV 02-26-2025
- FATE 02-24-2025
- Dividend Yield
- ZIMV N/A
- FATE N/A
- EPS Growth
- ZIMV N/A
- FATE N/A
- EPS
- ZIMV N/A
- FATE N/A
- Revenue
- ZIMV $451,294,000.00
- FATE $13,447,000.00
- Revenue This Year
- ZIMV $0.74
- FATE N/A
- Revenue Next Year
- ZIMV $1.23
- FATE N/A
- P/E Ratio
- ZIMV N/A
- FATE N/A
- Revenue Growth
- ZIMV 267.15
- FATE N/A
- 52 Week Low
- ZIMV $13.01
- FATE $1.04
- 52 Week High
- ZIMV $22.40
- FATE $8.83
- Technical
- Relative Strength Index (RSI)
- ZIMV 58.68
- FATE 34.56
- Support Level
- ZIMV $13.65
- FATE $1.22
- Resistance Level
- ZIMV $13.71
- FATE $1.36
- Average True Range (ATR)
- ZIMV 0.38
- FATE 0.14
- MACD
- ZIMV 0.07
- FATE -0.01
- Stochastic Oscillator
- ZIMV 83.24
- FATE 29.47
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.